- P-ISSN 1225-0163
- E-ISSN 2288-8985
The bioequivalence of two pioglitazone tablets, Actos<SUP>®</SUP> tablet (Takeda Chemical Industries, reference drug) and Pioglitazone tablet (Boryung Company, test drug) was evaluated according to the guidelines of Korea Food and Drug Administration. Twenty-eight healthy male Korean volunteers received each medicine (pioglitazone dose of 30 mg) in a 2×2 crossover study with one week washout interval. After drug administration, blood samples were collected at specific time intervals from 0-36 hours. The plasma concentrations of pioglitazone were determined by high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). The total chromatographic run time was 5 min and calibration curves were linear over the concentration range of 5-2000 ng/mL for pioglitazone. The method was validated for selectivity, sensitivity, linearity, accuracy and precision. The pharmacokinetic parameters were determined from the plasma concentration-time profiles of both formulations. The primary calculated pharmacokinetic parameters were compared statistically to evaluate bioequivalence between the two preparations. The 90% confidence intervals of the AUCt ratio and the C<SUB>max</SUB> ratio for Pioglitazone tablet and Actos<SUP>®</SUP> tablet were log0.9422~log1.1040 and log0.9200~log1.1556, respectively. Based on the statistical considerations, we can conclude that the test drug, Pioglitazone tablet was bioequivalent to the reference drug, Actos<SUP>®</SUP> tablet.
1. J. Waugh, G. M. Keating, G. L. Plosker, S. Easthope and D. M. Robinson, Drugs, 66, 85-109(2006).
2. Takeda Pharmaceutical Company Limited, Actos® (pioglitazone hydrochloride) Full Prescribing Information, Osaka, Japan, 2004, http://www.actos.com/pi.pdf.
3. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson and S. A. Kliewer, J. Biol. Chem., 270, 12953-12956(1995).
4. J. Sakamoto, H. Kimura, S. Moriyama, H. Odaka, Y. Momose, Y. Sugiyama and H. Sawada, Biochem. Biophys. Res. Commun., 278, 704-711 (2000).
5. J. Chilcott, MSc, P. Tappenden, M. L. Jones, M. A. DPhU and J. P. Wight, Clin. Therapeut., 23, 1792 (2001).
6. P. Sripalakit, P. Neamhom and A. Saraphanchotiwitthaya, J. Chromatogr. B, 843, 164-169(2006).
7. S. Wittayalertpanya, S. Chompootaweep and N. P. Thaworn, J. Med. Assoc. Thailand, 89, 2116-2122(2006).
8. 식품의약품안전청 고시 제 2007-65호, 생물학적동등 성시험기준 (2007. 09. 20).
9. Y. J. Xue, K. C. Turner, J. B. Meeker, J. Pursley, M. Arnold and S. Unger, J. Chromatogr. B, 795, 215- 226(2003).
10. International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Validation of analytical procedures, ICH-Q2A, Geneva, 1995.
11. FDA Guidelines, Bioequivalence Food and Drug Administration, Division of Bioequivalence, Office of Generic Drugs, Rockville, MD USA, 1992.